{
  "id": 1790,
  "text": "Corresponding response rates and survival are summarized in table 44 and table 45.# 14.1.5 (chemo)radiotherapy # LoE 3 As part of a small study, Marnitz et al.1709 evaluated the use of extended-field chemoradiation with concomitant chemotherapy in patients with histologically confirmed para-aortic metastases after laparoscopic para-aortic and pelvic lymphadenectomy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Corresponding response rates and survival are summarized in table 44 and table 45.# 14.1.5 (chemo)radiotherapy # LoE 3 As part of a small study, Marnitz et al.1709 evaluated the use of extended-field chemoradiation with concomitant chemotherapy in patients with histologically confirmed para-aortic metastases after laparoscopic para-aortic and pelvic lymphadenectomy.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在宫颈癌治疗中发现腹主动脉旁转移时，扩展野同步放化疗是一种重要的治疗方式。根据相关研究，小范围研究（如Marnitz等的研究）表明，对于经过腹腔镜腹主动脉及盆腔淋巴结清扫术后，组织学上确认有腹主动脉旁转移的患者，扩展野放疗联合同步化疗能够带来一定的治疗效果。\n\n效果评估通常从以下几个方面入手：\n\n1. **肿瘤反应率**：通过影像学（如CT、MRI及PET-CT）评估肿瘤体积变化及代谢情况以确定治疗后的客观反应率。\n   \n2. **局部控制率**：扩展野的同步放化疗能否有效控制腹主动脉旁及原发区域的病灶是关键的评估指标。\n\n3. **生存率**：包括无进展生存期（PFS）和总体生存率（OS）的具体数值，是评估长远疗效的重要标准。\n\n4. **毒副作用**：由于扩展野放疗涉及较大区域，需密切监测治疗相关的急性及晚期毒性反应，如胃肠道反应、骨髓抑制及放射性损伤。\n\n总的来说，尽管扩展野同步放化疗在腹主动脉旁转移的宫颈癌患者中显示出一定效果，但考虑到小样本研究的局限性，仍需结合患者的具体病情和治疗耐受性综合评估。",
  "query": "如果在宫颈癌治疗中发现腹主动脉旁转移，如何评估扩展野同步放化疗的效果？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 如果在宫颈癌治疗中发现腹主动脉旁转移，如何评估扩展野同步放化疗的效果？\n\n<reference text>: Corresponding response rates and survival are summarized in table 44 and table 45.# 14.1.5 (chemo)radiotherapy # LoE 3 As part of a small study, Marnitz et al.1709 evaluated the use of extended-field chemoradiation with concomitant chemotherapy in patients with histologically confirmed para-aortic metastases after laparoscopic para-aortic and pelvic lymphadenectomy.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在宫颈癌治疗中发现腹主动脉旁转移时，扩展野同步放化疗是一种重要的治疗方式。根据相关研究，小范围研究（如Marnitz等的研究）表明，对于经过腹腔镜腹主动脉及盆腔淋巴结清扫术后，组织学上确认有腹主动脉旁转移的患者，扩展野放疗联合同步化疗能够带来一定的治疗效果。\n\n效果评估通常从以下几个方面入手：\n\n1. **肿瘤反应率**：通过影像学（如CT、MRI及PET-CT）评估肿瘤体积变化及代谢情况以确定治疗后的客观反应率。\n   \n2. **局部控制率**：扩展野的同步放化疗能否有效控制腹主动脉旁及原发区域的病灶是关键的评估指标。\n\n3. **生存率**：包括无进展生存期（PFS）和总体生存率（OS）的具体数值，是评估长远疗效的重要标准。\n\n4. **毒副作用**：由于扩展野放疗涉及较大区域，需密切监测治疗相关的急性及晚期毒性反应，如胃肠道反应、骨髓抑制及放射性损伤。\n\n总的来说，尽管扩展野同步放化疗在腹主动脉旁转移的宫颈癌患者中显示出一定效果，但考虑到小样本研究的局限性，仍需结合患者的具体病情和治疗耐受性综合评估。"
}